Purchase this article with an account.
Patrick Yu-Wai-Man, Nancy J Newman, Valerio Carelli, Mark Moster, Catherine Vignal-Clermont, Alfredo A Sadun, Chiara La Morgia, Francesco Bandello, Lorena Castillo Campillo, Stephanie Leruez, Dean Cestari, Robert Foroozan, Rustum Karanjia, Laure Blouin, Magali Taiel, Jose Alain Sahel; Evaluation of the efficacy of rAAV2/2-ND4 gene therapy for Leber hereditary optic neuropathy compared with the natural history. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2676.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Two Phase 3 multicenter clinical trials, RESCUE (NCT02652767) and REVERSE (NCT02652780), showed unexpected sustained bilateral improvement of best-corrected visual acuity (BCVA) following unilateral injection of rAAV2/2-ND4 gene therapy in patients with Leber hereditary optic neuropathy (LHON). In this study, we compared the treatment effect of rAAV2/2-ND4 with an external control group of untreated patients.
The treated population consisted of 76 ND4-LHON subjects injected unilaterally with rAAV2/2-ND4 in the RESCUE and REVERSE trials, of which 62 subjects enrolled in a long-term follow-up study (NCT03406104). The untreated population included a total of 208 subjects: 23 ND4-LHON subjects enrolled in the REALITY LHON Registry (NCT03295071) and 185 ND4-LHON subjects with individual patient-level data collected from 10 natural history studies in the literature. To allow for comparison with the treated population, the untreated population included only patients who were at least 15 years old at onset of vision loss. A Locally Estimated Scatterplot Smoothing (LOESS), non-parametric, local regression model was used to represent the evolution of BCVA over time. Comparison of BCVA between treated and untreated patients was performed at 12, 18, 24, 36 and 48 months after onset of vision loss.
BCVA evolution in the treated patients showed gradual, progressive, and sustained improvement from Month 12 to the last available observation (on average 51.5 months), whereas no recovery was observed in the untreated patients. At Month 48, mean BCVA was 1.26 LogMAR for treated patients and 1.59 LogMAR for untreated patients, which is a difference of 0.33 LogMAR or 16.5 ETDRS letters equivalent (p<0.01 for Kruskal -Wallis and repeated measures tests).
This indirect comparison of 76 treated patients with an external control group of 208 untreated patients showed a clinically meaningful effect of gene therapy on visual outcomes in ND4-LHON patients.
This is a 2021 ARVO Annual Meeting abstract.
This PDF is available to Subscribers Only